Retroviridae Infections is an indication for drug development with over 520 pipeline drugs currently active. According to GlobalData, preregistered drugs for Retroviridae Infections have a 95.74% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Retroviridae Infections compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Retroviridae Infections overview
Retroviruses belong to a family of enveloped RNA viruses (Retroviridae) that infect vertebrates. A retrovirus is a type of virus that inserts a DNA copy of its RNA genome into the DNA of a host cell that it invades, thus changing the genome of that cell. The disease pathogenesis begins when HIV infects dendritic antigen processing cells (DC) in the oral and genital mucosa, attaching to these cells via a DC SIGN receptor on the cell surface. HIV particles are then transported to CD4+ helper T-cells where many cycles of infection are established in lymphoid tissues. Loss of function and death of CD4+ helper T-cells results in a drop in the helper T-cell count. Clinical disease progression is correlated with the loss of CD4+ cells and may take five to ten years to progress from primary infection to complete failure of the T-cell mediated immune response.
See Also:
For a complete picture of PTSR and LoA scores for drugs in Retroviridae Infections, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
